Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03099785
Recruitment Status : Recruiting
First Posted : April 4, 2017
Last Update Posted : February 7, 2020
Sponsor:
Information provided by (Responsible Party):
Cosmo Pharmaceuticals NV ( Cosmo Technologies Ltd )

Brief Summary:
The objective of this study is to evaluate the safety and efficacy Rifamycin SV-MMX® 600 mg tablets for patients with diarrhoea-predominant irritable bowel syndrome when administered two to three times daily.

Condition or disease Intervention/treatment Phase
Diarrhea-predominant Irritable Bowel Syndrome Drug: Rifamycin SV 600mg t.i.d. Drug: Rifamycin SV b.i.d. + Placebo Drug: Placebo t.i.d. Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 342 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
Actual Study Start Date : December 18, 2017
Estimated Primary Completion Date : May 31, 2020
Estimated Study Completion Date : July 28, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea

Arm Intervention/treatment
Active Comparator: Treatment group 1: dose regimen 1
Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
Drug: Rifamycin SV 600mg t.i.d.
Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet

Active Comparator: Treatment group 2: dose regimen 2
Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
Drug: Rifamycin SV b.i.d. + Placebo
Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet

Placebo Comparator: Treatment group 3: matching placebo
Rifamycin SV-MMX® matching placebo tablets, t.i.d.
Drug: Placebo t.i.d.
Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet




Primary Outcome Measures :
  1. Proportion of subjects with relief from abdominal pain and improved stool consistency. [ Time Frame: 88 days ]

    Proportion of weekly responders defined as subjects who weekly have relief of the composite of abdominal pain and stool consistency, on the basis of their daily assessments. Relief of abdominal pain is defined as a decrease in the weekly average of abdominal pain score of at least 30% compared with baseline and relief of stool consistency is defined as a 50% or greater reduction in the number of days per week with at least one stool that has a consistency of Type 6 or 7 compared with baseline.

    All participants will complete daily assessments of abdominal pain and stool consistency:

    • Abdominal Pain: Scored between 0 (no pain) and 10 (as bad as it could be)
    • Stool Consistency: Bristol Stool Scale (Scored 1-7)


Secondary Outcome Measures :
  1. Proportion of subjects with relief of global IBS symptoms during weeks 3-12 [Efficacy] [ Time Frame: 10 weeks ]
    Proportion of subjects with adequate relief of global IBS symptoms for at least 2 (consecutive or not) of the 10 weeks during the follow-up period (i.e., weeks 3 through 12). Adequate relief of global IBS symptoms is defined as a response of "yes" to the following question, which will be asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? [Yes/No]"

  2. Proportion of subjects with monthly relief of global IBS symptoms [Efficacy] [ Time Frame: 88 days ]
    Proportion of subjects with adequate relief of global IBS symptoms during at least 2 weeks (consecutive or not) per month ("monthly response") during month 1, during month 1 through 2 and during month 1 through 3 will be assessed to identify the onset and duration of the therapeutic effect.

  3. Proportion of subjects with relief of IBS-related bloating during weeks 3-12 [Efficacy] [ Time Frame: 10 weeks ]
    Proportion of subjects with adequate relief of IBS-related bloating for at least 2 (consecutive or not) of the 10 weeks during the follow-up period (i.e., weeks 3 through 12). Adequate relief of bloating is defined as a response of "yes" to the following question, which will be asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? [Yes/No]."

  4. Proportion of subjects with monthly relief of IBS-related bloating [Efficacy] [ Time Frame: 88 days ]
    Proportion of subjects with adequate relief of bloating during at least 2 weeks (consecutive or not) per month ("monthly response") during month 1, during month 1 through 2 and during month 1 through 3 will be assessed to identify the onset and duration of the therapeutic effect.

  5. Proportion of subjects with weekly relief of IBS symptoms, bloating and abdominal pain [Efficacy] [ Time Frame: 88 days ]

    Proportion of subjects with relief (weekly responders) determined from the subjects' daily assessments of IBS symptoms, bloating, and abdominal pain; relief of IBS symptoms and bloating is defined as a score of either 0 (not at all) or 1 (hardly) for at least 50% of the days in a given week or a score of 0 (not at all), 1 (hardly), or 2 (somewhat) for 100% of the days in a given week for at least 2 (consecutive or not) of the 4 weeks during a given month. Relief of abdominal pain is defined as a decrease by ≥30% from baseline in weekly mean rating of IBS-related abdominal pain.

    All participants will complete daily assessments of IBS symptoms, bloating and abdominal pain:

    • IBS Symptoms: Scored between 0 (Not bothersome at all) and 6 (a very great deal bothersome)
    • Bloating: Scored between 0 (not at all bothersome) and 6 (a very great deal bothersome)
    • Abdominal Pain: Scored between 0 (no pain) and 10 (as bad as it could be)

  6. Number of weeks of IBS-symptom relief during follow-up [Efficacy] [ Time Frame: 10 weeks ]
    Number of weeks (consecutive or not) subjects achieve adequate relief of IBS symptoms during the follow up period.

  7. Number of weeks of bloating relief during follow-up [Efficacy] [ Time Frame: 10 weeks ]
    Number of weeks (consecutive or not) subjects achieve adequate relief of bloating during the follow up period.

  8. Change in IBS-symptoms, bloating and abdominal pain from baseline to 12 weeks - captured by a daily diary [Efficacy] [ Time Frame: 12 weeks ]

    Change from baseline to week 12 in daily IBS symptoms, bloating and abdominal pain. This information will be captured in a daily diary by the participants.

    All participants will complete daily assessments of IBS symptoms, bloating and abdominal pain:

    • IBS Symptoms: Scored between 0 (Not bothersome at all) and 6 (a very great deal bothersome)
    • Bloating: Scored between 0 (not at all bothersome) and 6 (a very great deal bothersome)

  9. Proportion of monthly responders for IBS-symptoms, bloating and abdominal pain [Efficacy] [ Time Frame: 3 months ]

    Proportion of monthly responders during month 1, during month 1 through 2 and during month 1 through 3 determined from the subjects' daily assessments of IBS symptoms, bloating, and abdominal pain; relief of IBS symptoms and bloating is defined as a score of either 0 (not at all) or 1 (hardly) for at least 50% of the days in a given month or a score of 0 (not at all), 1 (hardly), or 2 (somewhat) for 100% of the days in a given month. Relief of abdominal pain is defined as a decrease by ≥30% from baseline in weekly mean rating of IBS-related abdominal pain. Relief of stool consistency is defined as a 50% or greater reduction in the number of days per month with at least one stool that has a consistency of Type 6 or 7 compared with baseline.

    Daily Assessments:

    • IBS Symptoms: Scored between 0 (Not bothersome at all) and 6 (a very great deal bothersome)
    • Bloating: Scored between 0 (not at all bothersome) and 6 (a very great deal bothersome)

  10. Change from baseline to each week during follow up for IBS-symptoms bloating, abdominal pain, stool consistency, urgency - captured by a daily diary [Efficacy] [ Time Frame: 12 weeks ]

    Change from baseline to each week during the 12 week follow up for daily IBS symptoms, bloating, abdominal pain, stool consistency and sense of urgency, asked as "Have you felt or experienced a sense of urgency today? [Yes/No]" and calculated as 100* (number of days with urgency/number of days with data), and daily number of stools. This information will be captured in a daily diary by the participants.

    All participants will complete daily assessments of IBS symptoms, bloating and abdominal pain:

    • IBS Symptoms: Scored between 0 (Not bothersome at all) and 6 (a very great deal bothersome)
    • Bloating: Scored between 0 (not at all bothersome) and 6 (a very great deal bothersome)
    • Stool Consistency: Bristol Stool Scale (Scored 1-7)
    • Urgency: Answered Yes or No

  11. Change from baseline at weeks 4, 8 and 12 in quality of life assessment [Efficacy] [ Time Frame: 12 weeks ]
    Change from baseline at weeks 4, 8 and 12 in quality of life inquired as IBS-QoL


Other Outcome Measures:
  1. Treatment Emergent Adverse Events [Safety] [ Time Frame: 12 weeks ]
    Monitoring of treatment emergent adverse events.

  2. Change from Baseline in Physical Exam [Safety] [ Time Frame: 12 weeks ]
    Changes from baseline in physical examination.

  3. Change from Baseline in Vital Signs [Safety] [ Time Frame: 12 weeks ]
    Changes from baseline in vital signs.

  4. Change from Baseline in Lab Tests [Safety] [ Time Frame: 12 weeks ]
    Changes from baseline in clinical laboratory tests.

  5. Change from Baseline in ECG [Safety] [ Time Frame: 12 weeks ]
    Changes from baseline in ECG.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Informed Consent: signed written informed consent before inclusion in the study
  2. Sex and Age: males/females, ≥18 year old
  3. IBS Diagnosis: confirmed IBS-D diagnosis per Rome IV criteria
  4. Symptoms: active symptoms of IBS at baseline (day 1) as measured by average daily scores for at least 7 days before baseline:

    1. abdominal pain score ≥3 using an 11-point numeric rating scale and
    2. bloating score: 2-4 inclusive and
    3. stool consistency: score 6 or 7 (measured by the Bristol stool form scale) for at least 2 days from day -7 to day -1

      and by a negative response to the global IBS symptom assessment question and to the IBS-related bloating assessment question both given weekly during the screening phase up to day 1 before randomisation:

    4. "In the past 7 days, have you had adequate relief of your IBS symptoms?" [No] and
    5. "In the past 7 days, have you had adequate relief of your IBS symptom of bloating?"[No]
  5. Colonoscopy: performed within 5 years; if patient's age >50, colonoscopy performed within 2 years
  6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the study
  7. Literacy: sufficiently literate to comply with the study requirement of using electronic diaries and filling in electronic forms
  8. Contraception and fertility: females of childbearing potential and fertile males must be using at least one reliable method of contraception.

Reliable methods of contraception for women include:

  1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit
  2. A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit

    Reliable methods of contraception for men and male partners of female patients include:

  3. Male condoms with spermicide

    Reliable methods of contraception for both women and men include:

  4. A sterile sexual partner or sexual abstinence Women of non-childbearing potential or in post-menopausal status for at least 1 year and sterile or surgically sterilised men will be admitted.

For women of childbearing potential, serum pregnancy test result must be negative at screening

Exclusion Criteria:

  1. IBS: symptoms of constipation at baseline:

    1. less than 3 bowel movements a week and
    2. stool consistency score ≤2 for ≥2 days in a week
  2. Screening phase: failure to record the daily symptom assessments in the diary cards for at least 7 days before baseline
  3. Gastroenteric: underlying gastrointestinal diseases including ulcerative colitis, Crohn's disease, pancreatitis, any active infectious, haemorrhagic or inflammatory disorder not related to IBS-D, gastrointestinal motility disorders such as ileus, gastroparesis or pseudoobstruction, gastroduodenal ulcer, gastrointestinal malignancy or potentially fatal diseases if not full in remission (5 years from diagnosis and without maintenance treatment), amyloidosis and cholelithiasis if cholecystectomy not performed
  4. Intolerance: ascertained underlying lactose intolerance with response to diet or any other malabsorption syndrome with the exclusion of asymptomatic lactose malabsorption
  5. Coeliac disease: ascertained or presumptive underlying coeliac disease
  6. Bile: ascertained or presumptive bile acid malabsorption or bile acid induced diarrhoea
  7. Diabetes: underlying diabetes type I or II
  8. Thyroid: abnormal thyroid function not controlled by thyroid medications
  9. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study
  10. Renal function: ascertained or presumptive clinically significant renal insufficiency or creatinine above twice the upper limit of normal (ULN) of the performing laboratory reference range
  11. Liver function: chronic liver disease or clinically significant liver enzyme abnormality as evidenced by elevated AST, ALT or total bilirubin >1.5 times ULN
  12. AIDS/HIV: ascertained or presumptive acquired immunodeficiency (AIDS) or known infection with human immunodeficiency virus (HIV)
  13. Diseases: significant history of medical or surgical conditions excluding hysterectomy, caesarean section, appendectomy, cholecystectomy, benign polypectomy and inguinal hernia and including renal, hepatic, cardiovascular, haematological, endocrine, immune, psychiatric or neurological diseases that in the investigator's opinion may interfere with the aim of the study; malignant diseases not in remission for at least 5 years
  14. Medications: alosetron, eluxadoline, ondansetron, tegaserod, lubiprostone, warfarin, antipsychotic, antispasmodic, prokinetic, antidiarrhoeal, laxative, probiotic, narcotic or antibiotic agents within 14 days before the screening visit; antidepressant agents of the selective serotonin-reuptake inhibitor and tricyclic classes unless taken at a stable dose for at least 6 weeks before the screening visit
  15. Investigational drugs: participation in the evaluation of any investigational product within 30 days before this study
  16. Drug and alcohol: known history of drug or alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to the USDA Dietary Guidelines 2015] abuse
  17. Pregnancy (females only): pregnant or lactating women or wishing to become pregnant in the 3 months following this visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03099785


Contacts
Layout table for location contacts
Contact: Emma O'Shea +35318170370 EOShea@cosmopharma.com

Locations
Show Show 30 study locations
Sponsors and Collaborators
Cosmo Technologies Ltd
Layout table for additonal information
Responsible Party: Cosmo Technologies Ltd
ClinicalTrials.gov Identifier: NCT03099785    
Other Study ID Numbers: CB-01-11/28
First Posted: April 4, 2017    Key Record Dates
Last Update Posted: February 7, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: None. IPD not to be shared.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Irritable Bowel Syndrome
Syndrome
Diarrhea
Disease
Pathologic Processes
Signs and Symptoms, Digestive
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Rifamycins
Rifamycin SV
Anti-Bacterial Agents
Anti-Infective Agents
Antirheumatic Agents